C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 27 PLN -0.18%
Market Cap: 1.5B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Celon Pharma SA
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
PP&E Net
zł323.8m
CAGR 3-Years
-1%
CAGR 5-Years
8%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
PP&E Net
zł10.6m
CAGR 3-Years
10%
CAGR 5-Years
32%
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
PP&E Net
zł180.2k
CAGR 3-Years
N/A
CAGR 5-Years
78%
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.4B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
9.2 PLN
Overvaluation 66%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's PP&E Net?
PP&E Net
323.8m PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's PP&E Net amounts to 323.8m PLN.

What is Celon Pharma SA's PP&E Net growth rate?
PP&E Net CAGR 5Y
8%

Over the last year, the PP&E Net growth was -7%. The average annual PP&E Net growth rates for Celon Pharma SA have been -1% over the past three years , 8% over the past five years .

Back to Top